- Home
- JRVR vs PROK Comparison
JRVR vs PROK Comparison
Compare JRVR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | PROK |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 296.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JRVR | PROK |
|---|---|---|
| Price | $6.16 | $1.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.33 | ★ $7.40 |
| AVG Volume (30 Days) | 181.7K | ★ 930.6K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $687,614,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | $7.84 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $4.54 | $0.54 |
| 52 Week High | $7.20 | $7.13 |
Technical Indicators
Market Signals| Indicator | JRVR | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 49.46 |
| Support Level | $6.15 | $1.71 |
| Resistance Level | $6.39 | $2.58 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.79 | 44.32 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.